
## Pierre-Yves Dietrich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5925072/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nature Reviews Neuroscience, 2022, 23, 53-66.	10.2	203
2	Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell, 2021, 39, 1091-1098.e2.	16.8	199
3	Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. Cancer Cell, 2017, 32, 856-868.e5.	16.8	121
4	Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. Oncolmmunology, 2018, 7, e1501137.	4.6	120
5	CAR T-Cell Therapies in Glioblastoma: A First Look. Clinical Cancer Research, 2018, 24, 535-540.	7.0	103
6	Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. Neuro-Oncology, 2019, 21, 923-933.	1.2	89
7	Peptides as cancer vaccines. Current Opinion in Pharmacology, 2019, 47, 20-26.	3.5	75
8	First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies. Oncolmmunology, 2017, 6, e1338235.	4.6	52
9	Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell–Mediated Antitumor Immunity. Cancer Research, 2015, 75, 3020-3031.	0.9	50
10	Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy. Science Immunology, 2021, 6, .	11.9	47
11	Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. OncoImmunology, 2018, 7, e1391972.	4.6	42
12	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. Frontiers in Oncology, 2016, 6, 256.	2.8	39
13	Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants. Molecular Therapy, 2016, 24, 1675-1685.	8.2	29
14	Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review. CNS Oncology, 2015, 4, 387-392.	3.0	28
15	Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma. Oncolmmunology, 2020, 9, 1779990.	4.6	28
16	Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma. Cancers, 2020, 12, 1423.	3.7	25
17	Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?. Cancer Treatment Reviews, 2021, 97, 102204.	7.7	24
18	ldentification of a novel population of highly cytotoxic câ€Metâ€expressing CD8 <sup>+</sup> T lymphocytes. EMBO Reports, 2017, 18, 1545-1558.	4.5	22

PIERRE-YVES DIETRICH

#	Article	IF	CITATIONS
19	Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing. PLoS ONE, 2016, 11, e0162105.	2.5	17
20	Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells. Communications Biology, 2021, 4, 718.	4.4	14
21	Diagnosis and treatment of follicular lymphoma: an update. Swiss Medical Weekly, 2018, 148, w14635.	1.6	12
22	Survivin in Brain Tumors: An Attractive Target for Immunotherapy. Journal of Neuro-Oncology, 2003, 64, 71-76.	2.9	9
23	Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients. Clinical and Developmental Immunology, 2013, 2013, 1-8.	3.3	9
24	Resources-Stratified Guidelines for Classical Hodgkin Lymphoma. International Journal of Environmental Research and Public Health, 2020, 17, 1783.	2.6	9
25	An Experimentally Defined Hypoxia Gene Signature in Glioblastoma and Its Modulation by Metformin. Biology, 2020, 9, 264.	2.8	7
26	Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin). JCI Insight, 2021, 6, .	5.0	7
27	Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer. Anticancer Research, 2016, 36, 2359-64.	1.1	7
28	Outcome of patients with nonmetastatic muscleâ€invasive bladder cancer not undergoing cystectomy after treatment with noncisplatinâ€based chemotherapy and/or radiotherapy: a retrospective analysis. Cancer Medicine, 2016, 5, 1098-1107.	2.8	6
29	Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland. Swiss Medical Weekly, 2018, 148, w14596.	1.6	6
30	Immunotherapy for Glioma: From Illusion to Realistic Prospects?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 51-59.	3.8	5
31	Cell-penetrating peptides—the Swiss Army knife of cancer vaccines. Oncolmmunology, 2016, 5, e1095435.	4.6	5
32	Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer. IScience, 2022, 25, 103699.	4.1	5
33	Early closure of fistula using neo-adjuvant intra-arterial chemotherapy in locally advanced anal cancer. Digestive and Liver Disease, 2017, 49, 1262-1266.	0.9	2
34	Upfront targeted therapy for symptomatic melanoma brain metastases: paradigm changing?. CNS Oncology, 2016, 5, 199-201.	3.0	1
35	Clonal Evolution of a High-Grade Pediatric Glioma With Distant Metastatic Spread. Neurology: Genetics, 2021, 7, e561.	1.9	1
36	Prolonged Versus Short-Duration Use of Nasogastric Tubes in Patients with Head and Neck Cancer During Radiotherapy Alone or Combined Chemoradiotherapy. Nutrition and Cancer, 2018, 70, 1069-1074.	2.0	0

#	Article	IF	CITATIONS
37	Modeling Poliovirus Infection Using Human Engineered Neural Tissue Enriched With Motor Neuron Derived From Embryonic Stem Cells. Frontiers in Cell and Developmental Biology, 2020, 8, 593106.	3.7	0
38	Outcome of patients with nonmetastatic, muscle-invasive bladder cancer (MIBC), not undergoing cystectomy, after treatment with non-cisplatin-based chemotherapy and/or radiotherapy: A retrospective analysis Journal of Clinical Oncology, 2013, 31, e15619-e15619.	1.6	0
39	Digital patient-reported outcomes and serological response to SARS-COV-2 vaccines in patients with cancer Journal of Clinical Oncology, 2022, 40, e13606-e13606.	1.6	Ο
40	DESC-1, a prospective study on epidemiologic factors influencing general population to engage with liquid biopsy based cancer screening Journal of Clinical Oncology, 2022, 40, e13630-e13630.	1.6	0